Archives
5-(N,N-dimethyl)-Amiloride Hydrochloride: Advancing NHE1 ...
5-(N,N-dimethyl)-Amiloride Hydrochloride: Advancing NHE1 Inhibitor Workflows
Principle and Setup: Na+/H+ Exchanger Inhibition in Modern Research
5-(N,N-dimethyl)-Amiloride (hydrochloride) (DMA), available from APExBIO as SKU C3505, is a crystalline solid renowned for its potent and selective inhibition of Na+/H+ exchanger (NHE) isoforms—specifically NHE1, NHE2, and NHE3. With Ki values of 0.02 µM (NHE1), 0.25 µM (NHE2), and 14 µM (NHE3), DMA provides unmatched specificity for dissecting the Na+/H+ exchanger signaling pathway. By blocking proton extrusion and sodium uptake, DMA directly modulates intracellular pH regulation and sodium ion transport—both critical in cardiovascular disease research and ischemia-reperfusion injury protection.
DMA’s mechanistic profile extends further: it inhibits ouabain-sensitive ATP hydrolysis, affects sodium-potassium ATPase activity, and reduces alanine uptake in hepatocytes, broadening its relevance to metabolism and ion transport studies. As a research tool, its solubility up to 30 mg/ml in DMSO or DMF and stable storage at -20°C make it compatible with a wide array of cell-based and tissue assays.
Step-by-Step Experimental Workflow Enhancements
1. Preparing DMA Solutions for In Vitro Applications
- Dissolution: Dissolve DMA powder in DMSO or DMF to prepare a high-concentration stock (e.g., 10–30 mg/ml). Vortex until fully dissolved; avoid excessive heating.
- Aliquoting: Dispense working aliquots to minimize freeze/thaw cycles. Store at -20°C and use solutions promptly, as long-term storage can compromise activity.
- Working Concentrations: For NHE1 inhibition in cell culture, typical final concentrations range from 0.01 to 10 µM, depending on the desired degree of exchanger blockade and cell type sensitivity.
2. Protocol Integration: Endothelial Injury and pH Regulation Assays
- Pre-treatment: Incubate cells (e.g., human microvascular endothelial cells, HMECs) with DMA for 30–60 minutes prior to injury induction (such as lipopolysaccharide (LPS) exposure or hypoxia/reoxygenation).
- Measurement: Assess endpoints including intracellular pH (using BCECF-AM dye), cell viability (MTT or CellTiter-Glo assays), and barrier function (transendothelial electrical resistance, TEER).
- Sample Controls: Include vehicle controls (DMSO/DMF only) and, where relevant, alternative NHE inhibitors (e.g., amiloride or EIPA) to benchmark specificity.
3. Quantitative Readouts and Data Capture
- pH Modulation: DMA’s high-affinity NHE1 inhibition allows researchers to reduce intracellular pH with sub-micromolar dosing, yielding robust and dose-dependent shifts measurable within minutes.
- Barrier Integrity: In endothelial injury models, DMA pre-treatment attenuates LPS-induced permeability increases, as measured by decreased protein leakage or improved TEER, supporting its utility in sepsis and vascular dysfunction studies.
For detailed scenario-driven guidance, the article Optimizing Endothelial Injury Assays with 5-(N,N-dimethyl)-Amiloride provides complementary protocols and troubleshooting strategies, ensuring reproducibility and sensitivity in advanced endothelial models.
Advanced Applications and Comparative Advantages
1. Ischemia-Reperfusion Injury and Cardiac Contractile Dysfunction
DMA’s role in ischemia-reperfusion injury protection is well-documented: by normalizing sodium levels and mitigating contractile dysfunction in cardiac tissues, it enables translational research into myocardial recovery and heart failure mechanisms. Comparative studies reveal that DMA’s selectivity for NHE1 over NHE4/5/7 minimizes off-target effects, a key advantage over older amiloride analogs.
2. Endothelial Injury and Sepsis Biomarker Discovery
The reference study (Moesin Is a Novel Biomarker of Endothelial Injury in Sepsis) highlights the complexity of endothelial dysfunction and the need for precise modulators of ion transport and pH. In this context, DMA’s ability to modulate intracellular pH provides a unique platform to study signaling pathways such as Rock1/MLC and NF-κB, which are implicated in vascular permeability and inflammatory responses. When paired with biomarker assays (e.g., moesin ELISA), DMA treatment can help dissect the causal role of pH and sodium flux in endothelial injury, thus extending the utility of molecular biomarker studies.
3. Comparative Interlinking with Peer Resources
- 5-(N,N-dimethyl)-Amiloride Hydrochloride: Illuminating Na+/H+ Exchanger Signaling complements this workflow by offering a systems-level perspective, connecting molecular inhibition to translational endpoints in cardiovascular and endothelial research.
- Scenario-Driven Insights: 5-(N,N-dimethyl)-Amiloride (hydrochloride) provides troubleshooting and reproducibility guidance, addressing common laboratory challenges in cell viability and pH regulation assays.
Troubleshooting and Optimization Tips
- Solubility Issues: If DMA appears incompletely dissolved, verify solvent freshness and temperature. Avoid aqueous solutions for primary stock preparation; use DMSO or DMF exclusively.
- Loss of Potency: Avoid repeated freeze/thaw cycles. Prepare fresh working solutions before each experiment, as activity can decline after prolonged storage even at -20°C.
- Cell Toxicity: At concentrations above 10 µM, some sensitive cell lines may exhibit off-target effects. Conduct dose-response pilot studies and include viability assays to confirm optimal dosing.
- Assay Interference: Ensure that vehicle concentrations (DMSO/DMF) remain below 0.1–0.5% v/v in final assay conditions to avoid solvent-induced artifacts.
- Batch-to-Batch Consistency: Source DMA from a trusted supplier such as APExBIO to ensure high purity and performance reproducibility—critical for longitudinal studies and cross-lab comparisons.
- Data Normalization: When analyzing pH or sodium flux data, normalize readings to baseline controls and verify with independent markers of cell viability or membrane integrity.
For more detailed troubleshooting scenarios and expert Q&A, refer to Scenario-Driven Insights: 5-(N,N-dimethyl)-Amiloride (hydrochloride), which extends the practical guidance offered here.
Future Outlook: From Molecular Inhibition to Translational Impact
As research into cardiovascular disease, sepsis, and metabolic dysfunction accelerates, the need for precise, selective Na+/H+ exchanger inhibitors grows. DMA’s unique combination of high-affinity NHE1 inhibition, minimal off-target action, and compatibility with advanced assay systems positions it as an essential reagent for next-generation studies in cardiac contractile dysfunction research and endothelial injury modeling.
Looking forward, integration of DMA into high-throughput screening platforms, multi-omics workflows, and in vivo disease models will further illuminate the roles of sodium ion transport and pH regulation in health and disease. The ongoing refinement of endothelial injury biomarkers, such as moesin, will benefit from DMA-modulated systems, as highlighted in the reference study Moesin Is a Novel Biomarker of Endothelial Injury in Sepsis.
For researchers seeking to accelerate breakthroughs in ion transport, signaling, and translational cardiovascular research, 5-(N,N-dimethyl)-Amiloride (hydrochloride) from APExBIO remains a gold standard, delivering validated performance and workflow flexibility. Harnessing its full potential will continue to drive innovation at the intersection of molecular pharmacology and disease modeling.